このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Fluorocholine PET/MR in Breast Cancer

2026年7月2日 更新者:Taipei Veterans General Hospital, Taiwan

Use of Imaging Markers by Fluorocholine PET/MR to Predict Molecular Subtypes and Clinical Outcomes of Breast Cancer: A Pilot Study

Objectives:

Our study is conducted to use the pre-treatment Fluorocholine (FCH) Positron emission tomography/magnetic resonance (PET/MR) imaging in breast cancer patients, to investigate whether the conventional PET/MR imaging markers (maximum standardized uptake value [SUVmax], MR spectroscopy-derived choline analysis, dynamic contrast-enhanced MRI, apparent diffusion coefficient [ADC] analysis), and FCH PET/MR radiomic features, deep learning (DL) analysis are associated with molecular subtypes, clinical outcomes, treatment response, survival, and which parameters are more accurate for predictive purposes.

Primary study purposes:

-To investigate whether the pre-treatment FCH PET/MR imaging parameters are associated with molecular subtypes of breast cancers, and to evaluate the diagnostic performance for predictive purposes.

Secondary study purposes:

-To investigate whether the pre-treatment FCH PET/MR imaging parameters are associated with the factors related to clinical outcomes (histologic grade, prognosis) and to analyze which parameters are more accurate for predictive purposes.

Test drug:

Name: 18F- Fluorocholine (18F-FCH) Dosage form: N-([18F]fluoromethyl)-2-hydroxy-N,N-dimethylethan-1-aminium Strength: 3-5 MBq/kg per patient (5-6 mCi/mL at time of injection (TOI)) Dosage and administration: Intravenous injection.fluoromethyl

Selection criteria:

  1. Women aged 25-75 years old.
  2. Women diagnosed with breast cancer by pathological diagnosis from a core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).
  3. Women whose Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and life expectancy at least 3 months.

調査の概要

状態

募集

詳細な説明

Study steps / procedures:

  1. The study participants will receive pre-treatment whole-body PET/MR and breast PET/MR examinations.
  2. The whole-body PET/MR:

(1). The participant will undergo NPO for at least 6 hours before the examination.

(2). After intravenous injection of 5-6 mCi 18F- Fluorodeoxyglucose (FDG), the participant will rest for approximately 60 minutes, followed by a 20-25-minute whole-body PET/MR examination. FDG is a commercially available PET tracer approved for clinical diagnosis.

3. PET/MR of the breast:

  1. . The participant will undergo fasting (nothing by mouth, nil per os [NPO]) for at least 6 hours before the examination.
  2. . After intravenous injection of 5-6 mCi/mL (at TOI) 18F-Fluorocholine (FCH), the study participant will take a 45-60-minute bed rest and then undergo a breast PET/MR with prone position. The breast PET/MR will take about 30-35 minutes. The intravenous injection of MRI contrast media will be performed during the examination (MRI-contrast agent, Dotarem [Gadoteric acid, Guerbet, France] is commercialized and routinely used in MRI examination). The dosage of MRI contrast media ranges from 10-15 cc according to various body weight (0.1mmol/Kg).

4. The whole-body FDG PET/MR, and the breast FCH PET/MR will be performed on different days (interval of at least 2 days).

5. The study results will be interpreted by board certified diagnostic radiologists and nuclear medicine physicians, and relayed to the patient's physicians for reference of clinical management.

6. The radiation dose (effective dose equivalent, EDE) of a whole-body FDG PET/MR measures about 6.6 millisievert [mSv], the EDE of a FCH breast PET/MR measures about 3.85 mSv, totally about 10.45 mSv, which is relatively equivalent to that of a chest CT scan (without and with contrast, 10.8 mSv), resulting in a very low estimated risk of secondary cancer (about 5/10000 to 7/10000). Most of the radioactivity from FDG and FCH will decay naturally, and only a minimal portion will be excreted through the urinary and hepatobiliary systems.

研究の種類

観察的

入学 (推定)

195

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Taiwan
      • Taipei、Taiwan、台湾、11217
        • 募集
        • Taipei Veterans General Hospital
        • コンタクト:
        • 主任研究者:
          • Jane Wang, M.D.
        • 副調査官:
          • Ling-Ming Tseng, M.D
        • 副調査官:
          • Ko-Han Lin, M.D.
        • 副調査官:
          • Yi-Fang Tsai, M.D.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

The study is conducted to use the pre-treatment FCH PET/MR in breast cancer patients, to investigate whether the conventional PET/MR imaging markers (SUVmax, MR spectroscopy-derived choline analysis, dynamic contrast-enhanced MRI, ADC analysis), and FCH PET/MR radiomic features, deep learning (DL) analysis are associated with molecular subtypes, clinical outcomes, treatment response, survival, and which parameters are more accurate for predictive purposes.

説明

Inclusion Criteria:

  • Women aged 25-75 years old.
  • Women diagnosed with breast cancer by pathological diagnosis from a core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).
  • Women whose ECOG performance status between 0-2 and life expectancy at least 3 months.

Exclusion Criteria:

  • Women who are unable to cooperate with the examinations
  • Women who are pregnant, lactating or are planning to be pregnant
  • Women with estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or acute renal failure within 3 months, past history of renal dialysis.
  • Past history of claustrophobia
  • Past history of anaphylactoid reactions to MRI contrast agents or PET tracer agents.
  • Women with cardiac pacemaker, aneurysmal clip, mechanical valve replacement, recently applied coronary artery stent (within 3 months).
  • Past history of breast cancer or other malignancy within 5 years.
  • Women who underwent chemotherapy within a year.
  • Women who are not suitable to join the study according to the assessment by investigators.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Single arm
Women diagnosed with breast cancer by pathological diagnosis from core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months who will undergo surgery (without preoperative neoadjuvant chemotherapy).
  1. The study participants will receive pre-treatment whole-body PET/MR and breast PET/MR examinations.
  2. The whole-body PET/MR.
  3. PET/MR of the breast.
  4. The whole-body FDG PET/MR, and the breast FCH PET/MR will be performed on different days (interval at least 2 days).
  5. The study results will be interpreted by board certified diagnostic radiologists and nuclear medicine physicians, and relayed to the patient's physicians for reference of clinical management.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Association Between Pre-treatment FCH PET/MR Parameters and Molecular Subtypes of Breast Cancer
時間枠:From enrollment to the end of study (follow up) at least 40 weeks.
To evaluate the association between pre-treatment FCH PET/MR imaging parameters and molecular subtypes of breast cancer, as well as their predictive diagnostic performance.
From enrollment to the end of study (follow up) at least 40 weeks.

二次結果の測定

結果測定
メジャーの説明
時間枠
To investigate whether the pre-treatment FCH PET/MR imaging parameters are associated with the factors related to clinical outcomes (histologic grade, prognosis) and to analyze which parameters are more accurate for predictive purposes.
時間枠:From enrollment, at least about 40 weeks (until the completion of chemotherapy, or when the surgical pathology comes out).
The results to be predicted, including: clinical outcomes (histologic grade, recurrence rate (at 1, 2, 5 years after surgery), survival (5-year overall survival and disease/recurrence-free survival).
From enrollment, at least about 40 weeks (until the completion of chemotherapy, or when the surgical pathology comes out).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年6月14日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2028年7月31日

試験登録日

最初に提出

2026年5月8日

QC基準を満たした最初の提出物

2026年5月8日

最初の投稿 (実際)

2026年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月6日

QC基準を満たした最後の更新が送信されました

2026年7月2日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する